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THE results of renal transplantation performed at the 28 transplant units in the
United Kingdom are now contrasted with each other in the annual reports ofUnited
Kingdom Transplant.' Units are not identifiable, to preserve the anonymity of the
less successful, but one unit is clearly more successful than the others. That unit is
the Belfast unit, as it is known to be the only unit with 80%o of the patients
transplanted alive with functioning kidneys two years later.2 The European average
is around 50 per cent,3 the United Kingdom median is 38 per cent4 and the least
successful United Kingdom units had a success rate of only 15 per cent.' The benefits
to individual patients, and the financial savings for health services resulting from all
units achieving an 80%o success rate would be considerable.
The reason for the successes in Belfast is a major point of discussion when
nephrologists and transplant surgeons meet. It is accepted that the mortality rate in a
series of transplant patients will vary dependant on case selection. Those who
transplant "high-risk" patients, for example diabetics, are likely to lose more
patients but why should some units have less severe rejections or rejection episodes
that are more successfully treated? This might also be a function of the patients
transplanted, but there is no known way to select a group of patients to achieve
results like those reported by Belfast, even in groups of patients who had had
previous transfusions which is known to improve results. It is possible that some of
the variability between units is the result of chance, but this seems unlikely because
results would then be expected to fluctuate widely from year to year, and this is not
the case.
The low doses of corticosteroids used by the Belfast group2 contrasts with larger
doses by other United Kingdom units, and much larger doses by many United States
units.5 The Oxford group did not get comparable results using a similar daily dose,6
but the treatment regimen used in Oxford differed in at least three respects from that
in Belfast: (1) a large dose of methyl prednisolone was given routinely 7 days after
transplant to anticipate the onset of rejection commonly seen at this time; (2) the
dose and duration of corticosteroid therapy given to treat a rejection episode was
different, and "bolus" doses of methyl prednisolone were used; (3) a twice daily
scheme of administration of prednisolone contrasting with the once daily morning
dose in Belfast was used.
The publications from Belfast and Oxford do not comment on the time and
frequency of administration, and the information was obtained by personal
communication. In most renal transplant units little attention has been given to the
time of day of drug administration, or to whether it is given once daily or in divided
doses. This criticism also applies to much other therapy in many conditions. Very
few publications provide details of timing and frequency of drug treatment, most
just state the total amounts given in each 24 hours. Is it possible that the timing of
medication is the critical detail that has allowed success in Belfast?
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replying who were using a once daily morning dose of prednisolone and
azathioprine.18 This timing of corticosteroid therapy reduces adrenopituitary
suppression and is widely, although not consistently, adopted in the alternate day
regimes used by some in the later stages of renal allograft care. It has not been
thought to be important in the immediate post-operative period when most
rejections occur, and when adrenopituitary suppression influencing later events
could be induced.
Pharmacological immunosuppression is essential for successful renal transplant-
ation except in identical twins. This may have attracted interest away from the
immunosuppressive effects ofendogenous corticosteroids. Prednisolone and similar
exogenous corticosteroids are quickly removed from the blood, having half-lives of
only a few hours. In a patient with no natural adrenal activity the blood
corticosteroid level will drop to sub-normal levels in the period preceding a dose,
unless these are very frequent. This is especially likely to happen in the early
morning because patients do not usually take prednisolone medication until
breakfast. If there is a functioning adrenopituitary axis there is a progressive rise in
cortisol well before breakfast; the normal morning surges of cortisol secretion
starting well before waking,' but a functioning adrenopituitary axis is only likely in
patients taking more than minimal doses ofcorticosteroids when they are ingested in
the morning7' 8 especially if they have been ingested at this time since the onset of
therapy.
In studies on healthy students we demonstrated that immune responses aregreater
when an antigenic stimulus in sensitised individuals is given at 0700 hours.9 We have
also suggested that the onset of renal allograft rejection in human transplant
recipients most frequently has its onset during the night, perhaps especially the latter
part ofthe night.'0 It may be argued that this is the time when the maximal immuno-
suppressive effect is needed. On treatment regimes which use divided doses morning
and evening the exogenous levels will be at their lowest level in the whole 24 hours at
this time and there will, due to adrenal suppression from the evening dose, probably
be no endogenous cortisol. In regimens with evening dosing alone there may be no
endogenous cortisol and little prednisolone in the morning either. If morning only
doses of prednisolone only are taken, as with the Belfast patients, there may be an
endogenous adrenal response which has not been inhibited by evening doses of
corticosteroid, and this may provide an important immunosuppressive effect prior
to ingestion of morning tablets.
Animal experiments, recently conducted in our laboratory,"' 12 provide some
support for this hypothesis. Rats exposed to methyl prednisolone at different times,
which coincide with single doses of the application of an antigenic challenge
producing a cell-mediated immune response, show more prolonged suppression of
the response at times when the methyl prednisolone should inhibit endogenous
corticosteroid production least. Studies recently reported by Leisti and his
colleagues '" demonstrated that relapse in steroid-sensitive nephrotic syndrome may
be most unlikely in the days of post-corticoid hypoadrenalism after discontinuing
therapy. Is it possible that the immunological processes responsible for transplant
rejection are inadequately suppressed during the period of iatrogenic hypo-
adrenalism that occurs daily in those taking evening steroids? Our own retrospective
51analysis, examining the development of rejection three months or more after
successful renal transplantation, suggests that graft damage from this is more likely
in those taking evening doses of immunosuppressives only. In those taking divided
doses, at least some of the drugs in the morning, greater numbers of grafts remain
free oflate rejection.'8 We have not kept patients on morning onlyregimens, but late
loss of grafts from rejection is most unusual in the Belfast patients taking morning
only doses.
The dose level at which morning doses persist to late evening, and so inhibits
endogenous production, is not certain. The large doses used in many transplant
units may persist to the evening and patients taking a high dose regime, even ifgiven
only in the morning, may have adrenopituitary suppression similar to that occurring
in those taking evening doses. It may be that a low total daily dose, 20 mg. daily for
the first six months, which is used by the Belfast unit and the fact that it is given as
one dose in the morning, usually 1000 hours, are both critical. Their use of "non-
enteric" coated tablets, which are more reliably absorbed,'4 and the ingestion of
tablets away from breakfast, which could also influence absorption, might also be
important.
There has been almost no interest in any clinical specialty about whether there
might be a best time of day to give immunosuppressive drugs other than cortico-
steroids. A few scientists have done many careful experiments which show that cure
rates in experimental cancer and leukaemia can be quite different with the same
doses ofdrugs at different times, for example 94 per cent cure rate with the best time
contrasting with 44 per cent at the worst times.'5 16 There may also be an important
synchronising effect between the timing of glucocorticoid therapy and the effect of
other drugs. Cell mitotic rates, which may reflect susceptibility to drug treatment,
have marked circadian rhythms."' These can be disrupted when corticosteroid
administration does not coincide with the endogenous adrenal rhythmicity,'7 and
inappropriately timed dosing of steroids might reduce the effectiveness, or increase
the toxicity, or other drugs.
If timing of drug therapy is important statements referring only to the total daily
dose of immunosuppression used, standard to nearly all papers on immuno-
suppression after transplantation, are inappropriately vague. The details about
timing included in this paper were only obtained by direct questioning of the units
concerned, and did not appear in their published papers. Patients themselves may
modify the pattern of drug ingestion, and in addition to the problem of some
patients who forget their tablets there are others who, even when instructed about
time of ingestion, will take them at other times.
It requires more research, both retrospective studies and prospective comparative
investigations, before it will be accepted that the time of administration is even
important, let alone critical, to transplant success. While further information is
awaited those caring for transplant patients may wonder whether the best rule is not
to copy the successful-and give all maintenance immunosuppressives as single
morning doses, as in Belfast.
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